PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas.

Refractory or relapsed diffuse large B-cell lymphoma (DLBCL) often associates with the activated B-cell-like (ABC) subtype and genetic alterations that drive constitutive NF-κB activation and impair B-cell terminal differentiation. Here, we show that DNA damage response by p53 is a central mechanism suppressing the pathogenic cooperation of IKK2ca-enforced canonical NF-κB and impaired differentiation resulting from Blimp1 loss in ABC-DLBCL lymphomagenesis. We provide evidences that the interplay between these genetic alterations and the tumor microenvironment select for additional molecular addictions that promote lymphoma progression, including aberrant coexpression of FOXP1 and the B-cell mutagenic enzyme activation-induced deaminase, and immune evasion through major histocompatibility complex class II downregulation, PD-L1 upregulation, and T-cell exhaustion. Consistently, PD-1 blockade cooperated with anti-CD20-mediated B-cell cytotoxicity, promoting extended T-cell reactivation and antitumor specificity that improved long-term overall survival in mice. Our data support a pathogenic cooperation among NF-κB-driven prosurvival, genetic instability, and immune evasion mechanisms in DLBCL and provide preclinical proof of concept for including PD-1/PD-L1 blockade in combinatorial immunotherapy for ABC-DLBCL.

[1]  J. Cerhan,et al.  Aggressive Lymphomas , 2020, Hematologic Malignancies.

[2]  Y. Yang,et al.  The Inhibitory Mechanisms of Tumor PD-L1 Expression by Natural Bioactive Gallic Acid in Non-Small-Cell Lung Cancer (NSCLC) Cells , 2020, Cancers.

[3]  Zekuan Xu,et al.  ZNF143 Suppresses Cell Apoptosis and Promotes Proliferation in Gastric Cancer via ROS/p53 Axis , 2020, Disease markers.

[4]  A. Österborg,et al.  Targeting the Immune Microenvironment in Lymphomas of B-Cell Origin: From Biology to Clinical Application , 2019, Cancers.

[5]  M. Shipp,et al.  Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  B. Heyman,et al.  New developments in immunotherapy for lymphoma , 2018, Cancer biology & medicine.

[7]  V. Seshan,et al.  Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay , 2018, Blood Cancer Journal.

[8]  Stefano Monti,et al.  Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes , 2018, Nature Medicine.

[9]  Roland Schmitz,et al.  Genetics and Pathogenesis of Diffuse Large B‐Cell Lymphoma , 2018, The New England journal of medicine.

[10]  M. Reth,et al.  Foxp1 controls mature B cell survival and the development of follicular and B-1 B cells , 2018, Proceedings of the National Academy of Sciences.

[11]  K. Young,et al.  PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. , 2018, Blood.

[12]  Peter K. Sorger,et al.  Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy , 2017, Cell.

[13]  S. Rodig,et al.  Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma. , 2017, Blood advances.

[14]  R. Davis,et al.  High Complete Response Rates with Pembrolizumab in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma: Results of an Open-Label, Phase II Study , 2017 .

[15]  M. Nussenzweig,et al.  The microanatomic segregation of selection by apoptosis in the germinal center , 2017, Science.

[16]  D. Dunson,et al.  Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma , 2017, Cell.

[17]  N. Chiorazzi,et al.  Novel Method for High-Throughput Full-Length IGHV-D-J Sequencing of the Immune Repertoire from Bulk B-Cells with Single-Cell Resolution , 2017, Front. Immunol..

[18]  M. Nussenzweig,et al.  Dopamine in germinal centers , 2017, Nature Immunology.

[19]  M. Amiot,et al.  p53 dysregulation in B-cell malignancies: More than a single gene in the pathway to hell. , 2017, Blood reviews.

[20]  Ryan D. Morin,et al.  Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact. , 2017, Blood.

[21]  A. Banham,et al.  The significance of FOXP1 in diffuse large B-cell lymphoma , 2017, Leukemia & lymphoma.

[22]  A. Goodman,et al.  PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas , 2017, Nature Reviews Clinical Oncology.

[23]  Wei Jiang,et al.  The Other Function: Class II-Restricted Antigen Presentation by B Cells , 2017, Front. Immunol..

[24]  I. Mellman,et al.  Elements of cancer immunity and the cancer–immune set point , 2017, Nature.

[25]  G. Hortobagyi,et al.  Deubiquitination and Stabilization of PD-L1 by CSN5. , 2016, Cancer cell.

[26]  P. Hensbergen,et al.  The small FOXP1 isoform predominantly expressed in activated B cell-like diffuse large B-cell lymphoma and full-length FOXP1 exert similar oncogenic and transcriptional activity in human B cells , 2016, Haematologica.

[27]  A. Tzankov,et al.  Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas. , 2016, Human pathology.

[28]  Kui Wu,et al.  Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas. , 2016, Blood.

[29]  R. Siebert,et al.  Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics , 2016, Nature Communications.

[30]  D. Heo,et al.  Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas , 2016, Histopathology.

[31]  M. Robinson,et al.  The hematopoietic oncoprotein FOXP1 promotes tumor cell survival in diffuse large B-cell lymphoma by repressing S1PR2 signaling. , 2016, Blood.

[32]  Haley O. Tucker,et al.  Subtype-specific addiction of the activated B-cell subset of diffuse large B-cell lymphoma to FOXP1 , 2016, Proceedings of the National Academy of Sciences.

[33]  Ryan D. Morin,et al.  Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas , 2015, Clinical Cancer Research.

[34]  S. Murphy,et al.  Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer. , 2015, Cancer research.

[35]  K. Akashi,et al.  Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. , 2015, Blood.

[36]  M. V. van Zelm,et al.  The forkhead transcription factor FOXP1 represses human plasma cell differentiation. , 2015, Blood.

[37]  A. Banham,et al.  FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas , 2015, Leukemia.

[38]  P. Hersey,et al.  Inducible but Not Constitutive Expression of PD-L1 in Human Melanoma Cells Is Dependent on Activation of NF-κB , 2015, PloS one.

[39]  L. Pasqualucci,et al.  The genetic landscape of diffuse large B-cell lymphoma. , 2015, Seminars in hematology.

[40]  A. Deal,et al.  FOXP1 potentiates Wnt/β-catenin signaling in diffuse large B cell lymphoma , 2015, Science Signaling.

[41]  M. Mokry,et al.  FOXP1 directly represses transcription of proapoptotic genes and cooperates with NF-κB to promote survival of human B cells. , 2014, Blood.

[42]  R. Gascoyne,et al.  The tumour microenvironment in B cell lymphomas , 2014, Nature Reviews Cancer.

[43]  K. Tarte,et al.  High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial , 2014, Leukemia.

[44]  A. Rosenwald,et al.  Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification. , 2013, Blood.

[45]  Bei Wang,et al.  p53 increases MHC class I expression by upregulating the endoplasmic reticulum aminopeptidase ERAP1 , 2013, Nature Communications.

[46]  O. Elemento,et al.  Downregulation of FOXP1 is required during germinal center B-cell function. , 2013, Blood.

[47]  T. Honjo,et al.  In Vivo Analysis of Aicda Gene Regulation: A Critical Balance between Upstream Enhancers and Intronic Silencers Governs Appropriate Expression , 2013, PloS one.

[48]  Yun Bai,et al.  NF-κB Plays a Key Role in Inducing CD274 Expression in Human Monocytes after Lipopolysaccharide Treatment , 2013, PloS one.

[49]  M. Nussenzweig,et al.  Chromosome translocation, B cell lymphoma, and activation-induced cytidine deaminase. , 2013, Annual review of pathology.

[50]  David Dunson,et al.  Genetic heterogeneity of diffuse large B-cell lymphoma , 2013, Proceedings of the National Academy of Sciences.

[51]  K. Vousden,et al.  p53 mutations in cancer , 2013, Nature Cell Biology.

[52]  W. Choi,et al.  Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. , 2012, Blood.

[53]  Stefano Monti,et al.  Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma. , 2012, Cancer cell.

[54]  Carol Prives,et al.  Mutant p53: one name, many proteins. , 2012, Genes & development.

[55]  L. Staudt,et al.  Pathogenesis of human B cell lymphomas. , 2012, Annual review of immunology.

[56]  Eric S. Lander,et al.  Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing , 2012, Proceedings of the National Academy of Sciences.

[57]  L. Rimsza,et al.  Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma. , 2012, Blood.

[58]  Roland Schmitz,et al.  Malignant pirates of the immune system , 2011, Nature Immunology.

[59]  Steven J. M. Jones,et al.  Frequent mutation of histone modifying genes in non-Hodgkin lymphoma , 2011, Nature.

[60]  Raul Rabadan,et al.  Analysis of the Coding Genome of Diffuse Large B-Cell Lymphoma , 2011, Nature Genetics.

[61]  G. Pinkus,et al.  Programmed Death Ligand 1 Is Expressed by Non–Hodgkin Lymphomas and Inhibits the Activity of Tumor-Associated T Cells , 2011, Clinical Cancer Research.

[62]  Kai Fu,et al.  Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  L. Pasqualucci,et al.  BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. , 2010, Cancer cell.

[64]  J. Kutok,et al.  Constitutive canonical NF-κB activation cooperates with disruption of BLIMP1 in the pathogenesis of activated B cell-like diffuse large cell lymphoma. , 2010, Cancer cell.

[65]  Nina M. Donghia,et al.  Widespread genomic breaks from activation-induced cytidine deaminase are prevented by homologous recombination , 2010, Nature Immunology.

[66]  M. Nussenzweig,et al.  Origin of Chromosomal Translocations in Lymphoid Cancer , 2010, Cell.

[67]  Keiichiro Suzuki,et al.  B cell–specific and stimulation-responsive enhancers derepress Aicda by overcoming the effects of silencers , 2010, Nature Immunology.

[68]  M. Nussenzweig,et al.  AID produces DNA double-strand breaks in non-Ig genes and mature B cell lymphomas with reciprocal chromosome translocations. , 2009, Molecular cell.

[69]  M. Nussenzweig,et al.  AID Is Required for the Chromosomal Breaks in c-myc that Lead to c-myc/IgH Translocations , 2008, Cell.

[70]  F. Alt,et al.  AID expression levels determine the extent of cMyc oncogenic translocations and the incidence of B cell tumor development , 2008, The Journal of experimental medicine.

[71]  D. Schatz,et al.  Two levels of protection for the B cell genome during somatic hypermutation , 2008, Nature.

[72]  L. Staudt,et al.  Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma. , 2007, Blood.

[73]  T. Ried,et al.  AID-deficient Bcl-xL transgenic mice develop delayed atypical plasma cell tumors with unusual Ig/Myc chromosomal rearrangements , 2007, The Journal of experimental medicine.

[74]  M. Olivier,et al.  Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database , 2007, Human mutation.

[75]  F. Papavasiliou,et al.  Regulation of AID expression in the immune response , 2007, The Journal of experimental medicine.

[76]  Takeshi Azuma,et al.  Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium , 2007, Nature Medicine.

[77]  L. Staudt,et al.  Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. , 2006, Blood.

[78]  Roger Sciammas,et al.  Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation. , 2006, Immunity.

[79]  J. Nardone,et al.  Foxp1 is an essential transcriptional regulator of B cell development , 2006, Nature Immunology.

[80]  W. Chan,et al.  Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas. , 2006, Blood.

[81]  Michel C. Nussenzweig,et al.  Role of genomic instability and p53 in AID-induced c-myc–Igh translocations , 2006, Nature.

[82]  Stefano Monti,et al.  Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma , 2006, The Journal of experimental medicine.

[83]  Ash A. Alizadeh,et al.  AID is expressed in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas and is not correlated with intraclonal heterogeneity , 2004, Leukemia.

[84]  M. Nussenzweig,et al.  AID Is Required for c-myc/IgH Chromosome Translocations In Vivo , 2004, Cell.

[85]  L. Staudt,et al.  Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. , 2004, Blood.

[86]  Antonio Lanzavecchia,et al.  Central memory and effector memory T cell subsets: function, generation, and maintenance. , 2004, Annual review of immunology.

[87]  Meland,et al.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[88]  Gouri Nanjangud,et al.  Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas , 2001, Nature.

[89]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[90]  Y. Nishimura,et al.  Induction of expression of MHC‐class‐II antigen on human thyroid carcinoma by wild‐type p53 , 1998, International journal of cancer.

[91]  Pål Sætrom,et al.  AID expression in B-cell lymphomas causes accumulation of genomic uracil and a distinct AID mutational signature. , 2015, DNA repair.

[92]  R. Gascoyne,et al.  Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. , 2015, Blood.

[93]  L. Staudt,et al.  Diffuse large B-cell lymphoma—treatment approaches in the molecular era , 2014, Nature Reviews Clinical Oncology.

[94]  L. Pasqualucci,et al.  AID is required for germinal center–derived lymphomagenesis , 2008, Nature Genetics.

[95]  F. Alt,et al.  Induction of Activation-induced Cytidine Deaminase Gene Expression by Il-4 and Cd40 Ligation Is Dependent on Stat6 and Nfkb , 2022 .